FluoSphera has developed an in vitro platform that combines up to seven human tissue models in a single well to predict drug efficacy and toxicity. The CHF 1.15 million raised, with a Swiss business angel co-leading, will fund commercial development and its AI capabilities.
- Announced on
- Round
- Undisclosed round
- Amount
- CHF 1.2 M
- Location
- Geneva
- Sector
- Biotech & life sciences
Investors
- Soulmates Ventures lead
- IndieBio New York
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic